Amsterdam UMC, University of Amsterdam, Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, the Netherlands.
Department of Molecular and Cellular Hemostasis, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands.
Thromb Res. 2018 Oct;170:97-101. doi: 10.1016/j.thromres.2018.08.014. Epub 2018 Aug 23.
Calibrated automated thrombography (CAT) is useful in monitoring the anticoagulant status of patients treated with direct oral anticoagulants (DOACs). This as well as other applications of the CAT are hampered by the wide inter-individual variation, making the diagnosis of the anticoagulant status of a patient on DOAC difficult when using normal pooled plasma as a reference. With dabigatran, the CAT is further hampered, as this direct thrombin inhibitor also inhibits the calibrator that is used in CAT. In this study we examined the added value of the universal DOAC adsorbent DOAC Stop in CAT. For this, we used normal pooled plasma spiked with apixaban, dabigatran, edoxaban or rivaroxaban, and performed CAT with 5 pM tissue factor. DOAC Stop effectively removed DOACs from plasma, leaving the DOAC Stop-treated plasma slightly more procoagulant compared to sham treated, non-anticoagulated plasma. Examining levels of natural coagulation inhibitors revealed a slight reduction in tissue factor pathway inhibitor upon DOAC Stop treatment. When DOAC Stop-treated plasma was used in the calibrator wells, normal unaffected calibration curves were observed, even when dabigatran was present. In conclusion, DOAC Stop can be used to abolish dabigatran influences of anticoagulated plasma when used in the calibrator wells. Also, the anticoagulant status of a DOAC treated patient can be diagnosed simply by comparing untreated plasma with the same plasma sample treated with DOAC Stop. Using this approach, a minor DOAC-independent increase in CAT response in the DOAC Stop-treated sample should be taken into account.
校准自动化血栓描记术(CAT)可用于监测接受直接口服抗凝剂(DOAC)治疗的患者的抗凝状态。这种以及 CAT 的其他应用受到个体间广泛差异的阻碍,使得使用正常混合血浆作为参考时,难以诊断接受 DOAC 治疗的患者的抗凝状态。对于达比加群,CAT 进一步受阻,因为这种直接凝血酶抑制剂也会抑制 CAT 中使用的校准剂。在这项研究中,我们研究了通用 DOAC 吸附剂 DOAC Stop 在 CAT 中的附加价值。为此,我们使用添加了阿哌沙班、达比加群、依度沙班或利伐沙班的正常混合血浆,并使用 5 pM 组织因子进行 CAT。DOAC Stop 可有效去除血浆中的 DOAC,与未处理的、未抗凝的血浆相比,经 DOAC Stop 处理的血浆稍微更促凝。检查天然凝血抑制剂的水平发现,在 DOAC Stop 处理后,组织因子途径抑制剂略有减少。当 DOAC Stop 处理的血浆用于校准器孔时,即使存在达比加群,也可以观察到正常且未受影响的校准曲线。总之,当在校准器孔中使用时,DOAC Stop 可用于消除抗凝血浆中达比加群的影响。此外,只需将未经处理的血浆与用 DOAC Stop 处理的相同血浆样本进行比较,即可诊断接受 DOAC 治疗的患者的抗凝状态。使用这种方法,应考虑 DOAC Stop 处理样本中 CAT 反应的轻微、与 DOAC 无关的增加。